Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Editas Medicine (EDIT) over the last 7 years, with Jun 2025 value amounting to -$1.2 million.

  • Editas Medicine's Gains from Investment Securities fell 1012.38% to -$1.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$6.4 million, marking a year-over-year decrease of 253.86%. This contributed to the annual value of -$3.4 million for FY2024, which is 200.93% down from last year.
  • According to the latest figures from Q2 2025, Editas Medicine's Gains from Investment Securities is -$1.2 million, which was down 13.95% from -$1.0 million recorded in Q1 2025.
  • Editas Medicine's 5-year Gains from Investment Securities high stood at $19.8 million for Q4 2022, and its period low was -$4.1 million during Q3 2024.
  • For the 3-year period, Editas Medicine's Gains from Investment Securities averaged around -$278,000, with its median value being -$565,000 (2024).
  • Per our database at Business Quant, Editas Medicine's Gains from Investment Securities skyrocketed by 1,918.01% in 2022 and then slumped by 1,012.38% in 2025.
  • Quarterly analysis of 5 years shows Editas Medicine's Gains from Investment Securities stood at $983,000 in 2021, then skyrocketed by 1,918.01% to $19.8 million in 2022, then crashed by 75.21% to $4.9 million in 2023, then crashed by 101.22% to -$60,000 in 2024, then plummeted by 1,012.38% to -$1.2 million in 2025.
  • Its last three reported values are -$1.2 million in Q2 2025, -$1.0 million for Q1 2025, and -$60,000 during Q4 2024.